42
CHANGE AGENTS
For Suchi Saria, the promise of AI isn’t about disruption or novelty. It’s about impact, making sure a powerful insight reaches the right person at the right time.
As founder and CEO of Bayesian Health, Saria is leading the charge to deliver meaningful and trustworthy AI to healthcare at the patient’s bedside. It’s a solution she’s been building for nearly a decade. And for her, delivering timely AI-enabled insights is not an abstract question of data and numbers. It’s about people—frontline care teams, patients, and their families. “I’ve seen too many cases where people I love could’ve had better outcomes if the right information had been surfaced just a little earlier,” she says. Saria grew up in Darjeeling, India, where she saw firsthand how gaps in care access and infrastructure could create delays in clinical identification that could turn treatable conditions into life-threatening events. Later, as a PhD student at Stanford and then as a professor at Johns Hopkins, she began to understand just how much information flows through a modern hospital and how little of it is harnessed to meaningfully improve care. “You’d be shocked,” she says.
“Hospitals generate terabytes of data, but most of it ends up in a black box. They’re data rich but insight poor.” She believed there had to be a better way to utilize data to help patients and providers. Saria fixated on the image of a nurse on the night shift scanning notes at 2 a.m., trying to make sense of a patient’s unexpected decline. In that moment, a timely signal or
subtle warning could make a life-saving difference. That kind of real-world application became the North Star vision for Bayesian, which she founded in 2016.
science, clinical partners wary of AI in high-stakes settings, and investors hesitant to back tools that didn’t fit into existing reimbursement models. But she stayed focused.
What makes her leadership distinctive isn’t just her technical depth but her fluency across disciplines. Saria moves seamlessly from machine learning architecture to clinical workflow to Food and Drug Administration regulation. She doesn’t romanticize AI, and she doesn’t overstate its capabilities. Instead, she pragmatically focuses on trust, context, and integration.
“In hard fields, it’s easy to get distracted chasing what’s shiny or marketable,” she says. “If you really want to change something fundamental, you have to do the unglamorous work. The integrations. The validations. The conversations with clinicians.”
“We’ve built a platform that clinicians actually want to use,” she says. “That sounds simple, but it’s incredibly rare.” Bayesian’s flagship platform continuously monitors patient data to identify subtle warning signs and help streamline workflows so care teams can intervene before situations become emergencies. In multiple hospital systems, Bayesian has helped detect life-threatening and very costly conditions like sepsis, clinical deterioration, and pressure injuries hours earlier than clinicians could on their own, giving caregivers precious time to act. The road hasn’t always been smooth. Early on, Saria faced skepticism from nearly every side: academic purists who questioned commercializing
In 2024, WebMD named Saria one of its Health Heroes for her contributions to real-world clinical AI. And last year, Bayesian was recognized by Time and Forbes for its work and awarded a major grant from the National Science Foundation to expand its platform modules. For Saria, however, the triumphs that matter most are in the faces of clinicians who say the system helped them catch clinical decline early and actively helped a patient’s care. Lasting change takes time. But with Bayesian’s success, Saria is already showing that the most important transformations don’t come from disrupting the system. They come from understanding it deeply, building what it actually needs, and constantly—and relentlessly—finding ways to improve.
CEO PROFILE